Literature DB >> 11929090

Macroprolactinoma associated with Cushing's disease, successfully treated with cabergoline.

G T'Sjoen1, I Defeyter, J Van De Saffele, R Rubens, M Vandeweghe.   

Abstract

Multiple pituitary hormone hypersecretions have already been described, but the co-occurrence of PRL and ACTH excess is very rare. To our knowledge, medical treatment with cabergoline only, avoiding pituitary surgery and radiotherapy in this type of tumor has never been reported before. This case report deals with a 31-yr-old man affected with a macroprolactinoma associated with a florid clinical image of Cushing's disease. Normalization of the prolactin levels and the disappearance of clinical and biochemical features of Cushing's disease were obtained after administration of medical treatment only.

Entities:  

Mesh：

Substances：

Year:  2002        PMID： 11929090     DOI： 10.1007/BF03343983

Source DB:  PubMed          Journal:  J Endocrinol Invest        ISSN： 0391-4097            Impact factor:   4.256


  19 in total

1.  Cyclic Cushing's disease in long-term remission with a daily low dose of bromocriptine.

Authors:  M Adachi; R Takayanagi; T Yanase; Y Sakai; S Ikuyama; H Nakagaki; Y Osamura; N Sanno; H Nawata
Journal:  Intern Med       Date:  1996-03       Impact factor: 1.271

2.  Two-step development of a pituitary adenoma: from hyperprolactinemic syndrome to Cushing's disease.

Authors:  R G Gheri; W Boddi; F Ammannati; J Olivotto; C Nozzoli; A Franchi; L Bordi; M L Luisi; P Mennonna
Journal:  J Endocrinol Invest       Date:  1997-04       Impact factor: 4.256

3.  Equine Cushing's disease: plasma immunoreactive proopiolipomelanocortin peptide and cortisol levels basally and in response to diagnostic tests.

Authors:  D N Orth; M A Holscher; M G Wilson; W E Nicholson; R E Plue; C D Mount
Journal:  Endocrinology       Date:  1982-04       Impact factor: 4.736

4.  Adrenocorticotropin-secreting pituitary adenomas originate from the anterior or the intermediate lobe in Cushing's disease: differences in the regulation of hormone secretion.

Authors:  S W Lamberts; S A de Lange; S Z Stefanko
Journal:  J Clin Endocrinol Metab       Date:  1982-02       Impact factor: 5.958

5.  Selective bilateral and simultaneous catheterization of the inferior petrosal sinus: CRF stimulates prolactin secretion from ACTH-producing microadenomas in Cushing's disease.

Authors:  H M Schulte; B Allolio; R W Günther; G Benker; W Winkelmann; E E Ohnhaus; D Reinwein
Journal:  Clin Endocrinol (Oxf)       Date:  1988-03       Impact factor: 3.478

6.  Growth hormone (GH) and prolactin (PRL) gene expression and immunoreactivity in GH- and PRL-producing human pituitary adenomas.

Authors:  J Li; L Stefaneanu; K Kovacs; E Horvath; H S Smyth
Journal:  Virchows Arch A Pathol Anat Histopathol       Date:  1993

7.  Cushing's disease presenting as amenorrhoea with hyperprolactinaemia: report of two cases.

Authors:  T H Jurney; H de Ruyter; R A Vigersky
Journal:  Clin Endocrinol (Oxf)       Date:  1981-06       Impact factor: 3.478

8.  Enhanced prolactin responsiveness to galanin in patients with Cushing's disease.

Authors:  C Invitti; F Pecori Giraldi; A Tagliaferri; M Scacchi; A Dubini; F Cavagnini
Journal:  Clin Endocrinol (Oxf)       Date:  1993-08       Impact factor: 3.478

9.  Pituitary adenomas in Cushing's disease: do they arise from the intermediate lobe?

Authors:  C Raffel; J E Boggan; L F Eng; R L Davis; C B Wilson
Journal:  Surg Neurol       Date:  1988-08

10.  Amenorrhea-galactorrhea associated with Cushing's disease due to pituitary tumor.

Authors:  S Rodriguez; M Alger; G Forsbach; S N Contreras; E S Canales; A Zarate
Journal:  J Endocrinol Invest       Date:  1981 Jan-Mar       Impact factor: 4.256
View more
  5 in total

Review 1.  The Treatment of Cushing's Disease.

Authors:  Rosario Pivonello; Monica De Leo; Alessia Cozzolino; Annamaria Colao
Journal:  Endocr Rev       Date:  2015-06-11       Impact factor: 19.871

2.  Dopamine agonist-responsive Cushing's disease.

Authors:  Gurpreet Anand; Andrea Bink; Felix Beuschlein; Christoph Schmid
Journal:  BMJ Case Rep       Date:  2019-02-13

3.  Effect of cabergoline treatment on Cushing's disease caused by aberrant adrenocorticotropin-secreting macroadenoma.

Authors:  T Miyoshi; F Otsuka; M Takeda; K Inagaki; J Suzuki; T Ogura; I Date; K Hashimoto; H Makino
Journal:  J Endocrinol Invest       Date:  2004-12       Impact factor: 4.256

4.  Effectiveness of cabergoline in monotherapy and combined with ketoconazole in the management of Cushing's disease.

Authors:  Lucio Vilar; Luciana A Naves; Monalisa F Azevedo; Maria Juliana Arruda; Carla M Arahata; Lidiane Moura E Silva; Rodrigo Agra; Lisete Pontes; Larissa Montenegro; José Luciano Albuquerque; Viviane Canadas
Journal:  Pituitary       Date:  2010-06       Impact factor: 4.107

5.  Hypersecretion of ACTH and PRL from pituitary adenoma in MEN1, adequately managed by medical therapy.

Authors:  Shinsuke Uraki; Hiroyuki Ariyasu; Asako Doi; Hiroto Furuta; Masahiro Nishi; Takeshi Usui; Hiroki Yamaue; Takashi Akamizu
Journal:  Endocrinol Diabetes Metab Case Rep       Date:  2017-04-06
  5 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.